Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oxford BioMedica
Oxford, Oxfordshire, United Kingdomoxb.com ↗
- Ownership
- Public · OXB
- Employees
- ~500
- Development stage
- Commercial
01
Overview
Leading global CDMO/platform provider enabling cell/gene therapies via advanced viral vectors used worldwide—including several marketed products—with deep expertise spanning R&D through commercial supply.
- Therapeutic areas
- OphthalmologyOncologyNeurology
- Modalities
- Gene therapyCell therapyViral vector
- Industry
- Contract Manufacturing Organization
02
Partnerships
Novartis CAR-T collaborationother major pharma partnerships
03
Financials
- Market cap
- $863.9M
- Total revenue
- $226M
- Enterprise value
- $975.6M
Beyond the preview
Go deeper on Oxford BioMedica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxford BioMedica.